Details
Stereochemistry | ACHIRAL |
Molecular Formula | C34H32N4O9 |
Molecular Weight | 640.6393 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1C(COC(=O)C2=CN=CC=C2)(COC(=O)C3=CN=CC=C3)CCCC1(COC(=O)C4=CN=CC=C4)COC(=O)C5=CN=CC=C5
InChI
InChIKey=VRAHPESAMYMDQI-UHFFFAOYSA-N
InChI=1S/C34H32N4O9/c39-28(24-6-1-12-35-16-24)44-20-33(21-45-29(40)25-7-2-13-36-17-25)10-5-11-34(32(33)43,22-46-30(41)26-8-3-14-37-18-26)23-47-31(42)27-9-4-15-38-19-27/h1-4,6-9,12-19,32,43H,5,10-11,20-23H2
DescriptionCurator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D01291
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D01291
Hypolipidemic agent, Nicomol is an ingredient of Cholexamin in Japan. Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched by KYORIN Pharmaceutical in 1971. It is indicated for the treatment of hyperlipemia, improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome.
Originator
Sources: http://www.kyorin-gr.co.jp/en/ir/pdf/ar13/01.pdf
Curator's Comment: Was launched in 1971
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q704S8 Gene ID: 311849.0 Gene Symbol: Crat Target Organism: Rattus norvegicus (Rat) Sources: http://www.ncbi.nlm.nih.gov/pubmed/6798192 |
|||
Target ID: CHEMBL5756 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6798192 |
|||
Target ID: WP1795 Sources: http://www.ncbi.nlm.nih.gov/pubmed/227232 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | Cholexamin Approved UseINDICATIONS:
Hyperlipemia
Improvement in peripheral circulatory disorder resulting from
the following diseases
Chilblain, limb arterial occlusive disease (obstructive
thromboarteritis and arteriosclerosis obliterans), Raynaud
syndrome Launch Date1970 |
|||
Primary | Cholexamin Approved UseINDICATIONS:
Hyperlipemia
Improvement in peripheral circulatory disorder resulting from
the following diseases
Chilblain, limb arterial occlusive disease (obstructive
thromboarteritis and arteriosclerosis obliterans), Raynaud
syndrome Launch Date1969 |
|||
Primary | Cholexamin Approved UseHyperlipemia
Improvement in peripheral circulatory disorder resulting from
the following diseases
Chilblain, limb arterial occlusive disease (obstructive
thromboarteritis and arteriosclerosis obliterans), Raynaud
syndrome Launch Date1970 |
PubMed
Title | Date | PubMed |
---|---|---|
Arrhythmogenic effects of acute free fatty acid mobilization on ischemic heart. | 1976 May 26-29 |
|
Effect of nicomol on HDL cholesterol level. | 1979 Aug |
|
Effect of nicomol on high density lipoprotein (HDL) subfractions, HDL2e and HDL3e, separated by electrophoresis. | 1981 Apr |
|
Effects of some hypolipidemic drugs on biochemical values and on hepatic peroxisomal enzymes of normolipemic rat. | 1981 Oct |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98151
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C008612
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
34081
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
C84011
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
2880
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
DTXSID9048722
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103919
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
27959-26-8
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
SUB09240MIG
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
100000084416
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
248-748-9
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
215U8X2R44
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
1917
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | |||
|
m844
Created by
admin on Fri Dec 15 15:57:52 GMT 2023 , Edited by admin on Fri Dec 15 15:57:52 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY